Abstract：
Although there have been advances in treating pediatric patients with acute myeloid leukemia (AML) in developed countries, outcomes in low- to middle-income countries remain poor. The goal of this study was to investigate the outcomes in children with AML who were treated at a tertiary care center in Thailand. We divided the study into 4 research periods based on the chemotherapy protocols employed. The 5-year probabilities of event-free survival (pEFS) rates for periods 1-4 were 19.0%, 20.6%, 17.4%, and 37.3% (p value = 0.32), while the 5-year probabilities of overall survival (pOS) rates were 19.0%, 24.7%, 18.7%, and 42.5% (p value = 0.18), respectively. The multivariable model indicated an improvement in 5-year pOS between periods 1 and 4 (p value = 0.04). Age, white blood cell count, and study period were significant predictors of survival outcomes. The pOS of AML patients improved over time, increasing from 19.0% to 42.5%.
摘要：
尽管发达国家在治疗小儿急性髓细胞性白血病（AML）方面取得了进展，中低收入国家的结果仍然很差。这项研究的目的是调查在泰国三级护理中心接受治疗的AML儿童的结局。我们根据所采用的化疗方案将研究分为4个研究期。第1-4期的无事件生存率（pEFS）的5年概率为19.0％，20.6%,17.4%,和37.3%(p值=0.32)，5年总生存率（pOS）为19.0%，24.7%,18.7%,和42.5%(p值=0.18)，分别。多变量模型表明在第1期和第4期之间的5年pOS有所改善(p值=0.04)。年龄,白细胞计数,和研究期间是生存结局的重要预测因素。AML患者的pOS随着时间的推移而改善，从19.0%上升到42.5%。
